BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hubbard JM, Mahoney MR, Loui WS, Roberts LR, Smyrk TC, Gatalica Z, Borad M, Kumar S, Alberts SR. Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). Target Oncol. 2017;12:201-209. [PMID: 27943153 DOI: 10.1007/s11523-016-0467-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Brown ZJ, Hewitt DB, Pawlik TM. Experimental drug treatments for hepatocellular carcinoma: Clinical trial failures 2015 to 2021. Expert Opin Investig Drugs 2022. [PMID: 35580650 DOI: 10.1080/13543784.2022.2079491] [Reference Citation Analysis]
2 Chen R, Li Q, Xu S, Ye C, Tian T, Jiang Q, Shan J, Ruan J. Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment. Cancer Cell Int 2022;22:73. [PMID: 35148789 DOI: 10.1186/s12935-021-02435-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Lu L, Zhan M, Li X, Zhang H, Dauphars DJ, Jiang J, Yin H, Li S, Luo S, Li Y, He Y. Clinically approved combination immunotherapy: Current status, limitations, and future perspective. Current Research in Immunology 2022;3:118-27. [DOI: 10.1016/j.crimmu.2022.05.003] [Reference Citation Analysis]
4 Zheng Q, Wang H, Hou W, Zhang Y. Use of Anti-angiogenic Drugs Potentially Associated With an Increase on Serum AST, LDH, CK, and CK-MB Activities in Patients With Cancer: A Retrospective Study. Front Cardiovasc Med 2021;8:755191. [PMID: 34926609 DOI: 10.3389/fcvm.2021.755191] [Reference Citation Analysis]
5 Momeny M, Shamsaiegahkani S, Kashani B, Hamzehlou S, Esmaeili F, Yousefi H, Irani S, Mousavi SA, Ghaffari SH. Cediranib, a pan-inhibitor of vascular endothelial growth factor receptors, inhibits proliferation and enhances therapeutic sensitivity in glioblastoma cells. Life Sci 2021;287:120100. [PMID: 34715143 DOI: 10.1016/j.lfs.2021.120100] [Reference Citation Analysis]
6 Yang S, Yang S, Zhang H, Hua H, Kong Q, Wang J, Jiang Y. Targeting Na+ /K+ -ATPase by berbamine and ouabain synergizes with sorafenib to inhibit hepatocellular carcinoma. Br J Pharmacol 2021. [PMID: 34233013 DOI: 10.1111/bph.15616] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
7 Shek D, Read SA, Nagrial A, Carlino MS, Gao B, George J, Ahlenstiel G. Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates. Oncologist 2021;26:e1216-25. [PMID: 33818870 DOI: 10.1002/onco.13776] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Zarębska I, Gzil A, Durślewicz J, Jaworski D, Antosik P, Ahmadi N, Smolińska-Świtała M, Grzanka D, Szylberg Ł. The clinical, prognostic and therapeutic significance of liver cancer stem cells and their markers. Clin Res Hepatol Gastroenterol 2021;45:101664. [PMID: 33667731 DOI: 10.1016/j.clinre.2021.101664] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Piñero F, Tanno M, Aballay Soteras G, Tisi Baña M, Dirchwolf M, Fassio E, Ruf A, Mengarelli S, Borzi S, Fernández N, Ridruejo E, Descalzi V, Anders M, Mazzolini G, Reggiardo V, Marciano S, Perazzo F, Spina JC, McCormack L, Maraschio M, Lagues C, Gadano A, Villamil F, Silva M, Cairo F, Ameigeiras B; Argentinean Association for the Study of Liver Diseases (A.A.E.E.H). Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. Ann Hepatol 2020;19:546-69. [PMID: 32593747 DOI: 10.1016/j.aohep.2020.06.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 El Dika I, Makki I, Abou-Alfa GK. Hepatocellular carcinoma, novel therapies on the horizon. Chin Clin Oncol 2021;10:12. [PMID: 32527116 DOI: 10.21037/cco-20-113] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Fan G, Wei X, Xu X. Is the era of sorafenib over? A review of the literature. Ther Adv Med Oncol 2020;12:1758835920927602. [PMID: 32518599 DOI: 10.1177/1758835920927602] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
12 Piñero F, Silva M, Iavarone M. Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors. World J Gastroenterol 2020; 26(16): 1888-1900 [PMID: 32390700 DOI: 10.3748/wjg.v26.i16.1888] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
13 Cervello M, Emma MR, Augello G, Cusimano A, Giannitrapani L, Soresi M, Akula SM, Abrams SL, Steelman LS, Gulino A, Belmonte B, Montalto G, McCubrey JA. New landscapes and horizons in hepatocellular carcinoma therapy. Aging (Albany NY) 2020;12:3053-94. [PMID: 32018226 DOI: 10.18632/aging.102777] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
14 Lee A, Lee FC. Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check. Front Med 2020;14:273-83. [PMID: 31863306 DOI: 10.1007/s11684-019-0728-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
15 Li H, Xu K, Pian G, Sun S. Artesunate and sorafenib: Combinatorial inhibition of liver cancer cell growth. Oncol Lett 2019;18:4735-43. [PMID: 31611983 DOI: 10.3892/ol.2019.10810] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
16 Saffo S, Taddei TH. Systemic Management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment Strategies. Dig Dis Sci. 2019;64:1016-1029. [PMID: 30887150 DOI: 10.1007/s10620-019-05582-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
17 Raoul JL, Gilabert M, Adhoute X, Edeline J. An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma. Expert Opin Pharmacother. 2017;18:1467-1476. [PMID: 28893090 DOI: 10.1080/14656566.2017.1378346] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
18 Le Grazie M, Biagini MR, Tarocchi M, Polvani S, Galli A. Chemotherapy for hepatocellular carcinoma: The present and the future. World J Hepatol 2017; 9(21): 907-920 [PMID: 28824742 DOI: 10.4254/wjh.v9.i21.907] [Cited by in Crossref: 96] [Cited by in F6Publishing: 91] [Article Influence: 19.2] [Reference Citation Analysis]